• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Business news
  • PolyPeptide wins Malmö Life Science Business Award

PolyPeptide wins Malmö Life Science Business Award

28 June 2022
Business news

Malmö, 21 June 2022

We are proud of our site in Malmö, Sweden, for winning the Life Science Business Award of the city (Malmö Näringslivspris Life Science). The jury stressed the important role of PolyPeptide as part of Malmö’s Life Science cluster, recognizing the continued growth and positive developments as a high-quality, responsible employer.

Jens Fricke, the site director of PolyPeptide in Malmö, commented: “I would like to thank all the employees: The award reflects their efforts, engagement, and our great team spirit. We ultimately work to the benefit of millions of patients and see the award as an additional motivation to keep up the good work!”.

As per the end of 2021, PolyPeptide had 293 people employed in Malmö, with hiring ongoing to keep up with business growth. The company has its heritage in the city, where the manufacturing of Peptides started in 1952. Over the last 70 years, PolyPeptide developed into a contract development and manufacturing organization with over 1’100 employees globally, supporting customers worldwide with the development and manufacturing of innovative peptide- and oligonucleotides-based drugs.

Download PDF

Back to news

Related posts

24 April 2025

Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial


Read more
27 August 2024

Vinnova grant awarded to joint project between PolyPeptide and Red Glead Discovery for developing a more sustainable manufacturing method for a GLP-1 agonist.


Read more
8 May 2023

PolyPeptide launches new “Innovation Lab”


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers